Drug intelligence / Profile preview

BBP-454

Development stage: Preclinical
Lead developer: BridgeBio Pharma
Modality: Small Molecules

Overview

BBP-454 is a **small molecule pan-inhibitor of KRAS** currently in preclinical development. It acts by **inhibiting KRAS protein**, a GTPase involved in intracellular signaling pathways that drive proliferation and survival in many cancers, especially those with KRAS mutations. BBP-454 is designed to target a broad range of oncogenic KRAS variants, potentially including G12 and G13 oncoproteins. The drug aims to offer therapeutic options for patients with gastrointestinal and lung cancers that harbor these mutations. BBP-454 was originally developed at the University of California, San Francisco, and is now in development by BridgeBio Oncology Therapeutics (formerly TheRas, a subsidiary of BridgeBio)[1][3][6][11].

Other names: BBP 454BBP454BBP-454

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on BBP-454.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BBP-454.

Explore the full profile